DelMar Pharmaceuticals Inc (NASDAQ:DMPI), a USD$18.88M small-cap, is a healthcare company operating in an industry, which faces key trends such as rising demand fuelled by an aging population and the growing prevalence of chronic diseases. Healthcare analysts are forecasting for the entire industry, a somewhat weaker growth of 6.42% in the upcoming year, and a massive growth of 43.65% over the next couple of years. Not surprisingly, this rate is more than double the growth rate of the US stock market as a whole. Today, I will analyse the industry outlook, as well as evaluate whether DMPI is lagging or leading in the industry. View our latest analysis for DelMar Pharmaceuticals
What’s the catalyst for DMPI's sector growth?
New R&D methods and big data analytics are creating opportunities for innovations, however, stakeholders have been challenged to keep abreast of this structural shift while under pressure to cut costs. In the previous year, the industry endured negative growth of -60.80%, underperforming the US market growth of 4.49%. DMPI leads the pack with its impressive earnings growth of 11.43% over the past year. Furthermore, analysts are expecting this trend of above-industry growth to continue, with DMPI poised to deliver a 13.10% growth over the next couple of years.
Is DMPI and the sector relatively cheap?
Biotech companies are typically trading at a PE of 31x, higher than the rest of the US stock market PE of 22x. This illustrates a somewhat overpriced sector compared to the rest of the market. However, the industry did return a higher 15.86% compared to the market’s 9.99%, which may be indicative of past tailwinds. Since DMPI’s earnings doesn’t seem to reflect its true value, its PE ratio isn’t very useful. A loose alternative to gauge DMPI’s value is to assume the stock should be relatively in-line with its industry.
What this means for you:
Are you a shareholder? DMPI’s industry-beating future is a positive for shareholders, indicating they’ve backed a fast-growing horse. If you’re bullish on the stock and well-diversified by industry, you may decide to hold onto DMPI as part of your portfolio. However, if you’re relatively concentrated in biotech, you may want to value DMPI based on its cash flows to determine if it is overpriced based on its current growth outlook.
Are you a potential investor? If DMPI has been on your watchlist for a while, now may be the time to enter into the stock, if you like its growth prospects and are not highly concentrated in the biotech industry. Before you make a decision on the stock, take a look at DMPI’s cash flows and assess whether the stock is trading at a fair price.
For a deeper dive into DelMar Pharmaceuticals's stock, take a look at the company's latest free analysis report to find out more on its financial health and other fundamentals. Interested in other healthcare stocks instead? Use our free playform to see my list of over 1000 other healthcare companies trading on the market.
To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.
The author is an independent contributor and at the time of publication had no position in the stocks mentioned.